Diagnostic Criteria for Familial Mediterranean Fever
FMF diagnosis is primarily clinical, and the most widely validated criteria are the Tel-Hashomer criteria, which require 1 major criterion OR 2 minor criteria for diagnosis, achieving >95% sensitivity and >97% specificity 1.
Primary Diagnostic Approach
The diagnosis of FMF should ideally be made by a physician with experience in autoinflammatory diseases 2. While genetic testing of the MEFV gene provides supportive evidence, diagnosis remains fundamentally clinical 3.
Tel-Hashomer Criteria (Most Validated)
Major Criteria:
- Recurrent febrile episodes with serositis (peritonitis, pleuritis, or synovitis)
- AA amyloidosis without predisposing disease
- Favorable response to continuous colchicine treatment
Minor Criteria:
- Recurrent febrile episodes
- Erysipelas-like erythema
- FMF in a first-degree relative
Diagnosis requires: 1 major criterion OR 2 minor criteria 1
Alternative Criteria Systems
Pediatric Criteria (2009): At least 2 of 5 specific pediatric criteria achieve 89% sensitivity and 85% specificity in children, making them feasible for pediatric diagnosis 4.
Eurofever/PRINTO Classification Criteria (2019): These demonstrate 94% sensitivity and 91% specificity, and are increasingly used for both diagnosis and research purposes 4.
Clinical Features to Assess
Attack Characteristics:
- Duration: Typically 12-72 hours, with most attacks lasting <48 hours 5, 6
- Fever: May not be documented at presentation (only 19.6% in one cohort) 5
- Abdominal pain: Most common presentation (62.1% of patients) 5
- Chest pain and arthritis: Additional serositis manifestations 6
Key Historical Elements:
- Ethnicity: Mediterranean ancestry (Arabs, Armenians, Turks, Jews) 6
- Family history: Present in approximately 33% of cases 5
- Parental consanguinity: Found in ~25% of patients 5
- Age of onset: Typically begins in childhood
Genetic Testing Role
MEFV gene testing supports but does not establish the diagnosis 3. In Egyptian populations, E148Q is the most common allele (39.5%), followed by M694I (16.3%) 5. However, 93.6% of clinically diagnosed FMF patients carry at least one MEFV variant, meaning genetic testing has limitations and cannot rule out FMF if negative 5.
Important caveat: Homozygosity for M694V is associated with more severe disease and higher amyloidosis risk, which influences treatment intensity 2.
Laboratory Markers
Acute phase reactants should be measured:
- Serum amyloid A (SAA) protein - preferred marker 2
- C-reactive protein (CRP) - acceptable alternative if SAA unavailable 2
Note that SAA may be normal in 47.5% of patients at baseline 5, so normal inflammatory markers do not exclude FMF.
Diagnostic Pitfalls to Avoid
- Do not wait for genetic confirmation to start treatment if clinical suspicion is high 2
- Consider other diagnoses during attacks - patients with FMF can develop appendicitis or other acute conditions 2
- Atypical presentations may cause significant diagnostic delay 3
- Overlapping symptoms with other autoinflammatory diseases require careful differentiation 7
Colchicine as Diagnostic Tool
The remarkable efficacy of colchicine in FMF supports its use as a diagnostic tool - a favorable response to colchicine treatment strengthens the diagnosis and can be initiated before diagnostic certainty is achieved 2. This approach is particularly valuable given that FMF diagnosis remains clinical even with available genetic testing.